Continuing versus new prescriptions for sedative-hypnotic medications: United States, 2005-2012

Christopher N. Kaufmann, Adam P Spira, Colin A. Depp, Ramin Mojtabai

Research output: Contribution to journalReview article

Abstract

Objectives.To assess trends in continuing and new prescriptions for sedative-hypnotic medications, including benzodiazepines (BZDs) and non-BZD receptor agonists (nBZRAs). Methods. Data came from the National Ambulatory Medical Care Survey and comprised 287 288 randomly sampled patient visits. Physicians reported medications prescribed and whether they were "continuing" or "new" prescriptions. We assessed trends in continuing BZD, new BZD, continuing nBZRA, and new nBZRA prescriptions from 2005 to 2012. Results. Proportions of visits with continuing prescriptions increased from 3.4% in 2005 to 4.7% in 2012 (P < .01) for BZDs, and from 1.0% to 1.7% (P < .01) for nBZRAs. We noted no changes in new prescriptions. We observed the same patterns across patient age and physician specialties, except psychiatry. Despite no growth over time, the prevalence of visits involving continuing and new BZD and nBZRA prescriptions was much higher in psychiatry than in primary care and other specialties. Conclusions. Increased sedative-hypnotic prescribing in recent years may be attributable to long-Term growth in continuing prescriptions, rather than new prescriptions. Public Health Implications. Findings call for renewed efforts to limit continuing prescribing of sedative-hypnotics to reduce their use in the population.

Original languageEnglish (US)
Pages (from-to)2019-2025
Number of pages7
JournalAmerican Journal of Public Health
Volume106
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Hypnotics and Sedatives
Prescriptions
Benzodiazepines
Psychiatry
Health Care Surveys
Physicians
Growth
Primary Health Care
Public Health
Population

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Continuing versus new prescriptions for sedative-hypnotic medications : United States, 2005-2012. / Kaufmann, Christopher N.; Spira, Adam P; Depp, Colin A.; Mojtabai, Ramin.

In: American Journal of Public Health, Vol. 106, No. 11, 01.11.2016, p. 2019-2025.

Research output: Contribution to journalReview article

@article{812c021174354854832d63e952cf7e33,
title = "Continuing versus new prescriptions for sedative-hypnotic medications: United States, 2005-2012",
abstract = "Objectives.To assess trends in continuing and new prescriptions for sedative-hypnotic medications, including benzodiazepines (BZDs) and non-BZD receptor agonists (nBZRAs). Methods. Data came from the National Ambulatory Medical Care Survey and comprised 287 288 randomly sampled patient visits. Physicians reported medications prescribed and whether they were {"}continuing{"} or {"}new{"} prescriptions. We assessed trends in continuing BZD, new BZD, continuing nBZRA, and new nBZRA prescriptions from 2005 to 2012. Results. Proportions of visits with continuing prescriptions increased from 3.4{\%} in 2005 to 4.7{\%} in 2012 (P < .01) for BZDs, and from 1.0{\%} to 1.7{\%} (P < .01) for nBZRAs. We noted no changes in new prescriptions. We observed the same patterns across patient age and physician specialties, except psychiatry. Despite no growth over time, the prevalence of visits involving continuing and new BZD and nBZRA prescriptions was much higher in psychiatry than in primary care and other specialties. Conclusions. Increased sedative-hypnotic prescribing in recent years may be attributable to long-Term growth in continuing prescriptions, rather than new prescriptions. Public Health Implications. Findings call for renewed efforts to limit continuing prescribing of sedative-hypnotics to reduce their use in the population.",
author = "Kaufmann, {Christopher N.} and Spira, {Adam P} and Depp, {Colin A.} and Ramin Mojtabai",
year = "2016",
month = "11",
day = "1",
doi = "10.2105/AJPH.2016.303382",
language = "English (US)",
volume = "106",
pages = "2019--2025",
journal = "American Journal of Public Health",
issn = "0090-0036",
publisher = "American Public Health Association Inc.",
number = "11",

}

TY - JOUR

T1 - Continuing versus new prescriptions for sedative-hypnotic medications

T2 - United States, 2005-2012

AU - Kaufmann, Christopher N.

AU - Spira, Adam P

AU - Depp, Colin A.

AU - Mojtabai, Ramin

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objectives.To assess trends in continuing and new prescriptions for sedative-hypnotic medications, including benzodiazepines (BZDs) and non-BZD receptor agonists (nBZRAs). Methods. Data came from the National Ambulatory Medical Care Survey and comprised 287 288 randomly sampled patient visits. Physicians reported medications prescribed and whether they were "continuing" or "new" prescriptions. We assessed trends in continuing BZD, new BZD, continuing nBZRA, and new nBZRA prescriptions from 2005 to 2012. Results. Proportions of visits with continuing prescriptions increased from 3.4% in 2005 to 4.7% in 2012 (P < .01) for BZDs, and from 1.0% to 1.7% (P < .01) for nBZRAs. We noted no changes in new prescriptions. We observed the same patterns across patient age and physician specialties, except psychiatry. Despite no growth over time, the prevalence of visits involving continuing and new BZD and nBZRA prescriptions was much higher in psychiatry than in primary care and other specialties. Conclusions. Increased sedative-hypnotic prescribing in recent years may be attributable to long-Term growth in continuing prescriptions, rather than new prescriptions. Public Health Implications. Findings call for renewed efforts to limit continuing prescribing of sedative-hypnotics to reduce their use in the population.

AB - Objectives.To assess trends in continuing and new prescriptions for sedative-hypnotic medications, including benzodiazepines (BZDs) and non-BZD receptor agonists (nBZRAs). Methods. Data came from the National Ambulatory Medical Care Survey and comprised 287 288 randomly sampled patient visits. Physicians reported medications prescribed and whether they were "continuing" or "new" prescriptions. We assessed trends in continuing BZD, new BZD, continuing nBZRA, and new nBZRA prescriptions from 2005 to 2012. Results. Proportions of visits with continuing prescriptions increased from 3.4% in 2005 to 4.7% in 2012 (P < .01) for BZDs, and from 1.0% to 1.7% (P < .01) for nBZRAs. We noted no changes in new prescriptions. We observed the same patterns across patient age and physician specialties, except psychiatry. Despite no growth over time, the prevalence of visits involving continuing and new BZD and nBZRA prescriptions was much higher in psychiatry than in primary care and other specialties. Conclusions. Increased sedative-hypnotic prescribing in recent years may be attributable to long-Term growth in continuing prescriptions, rather than new prescriptions. Public Health Implications. Findings call for renewed efforts to limit continuing prescribing of sedative-hypnotics to reduce their use in the population.

UR - http://www.scopus.com/inward/record.url?scp=84990857135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990857135&partnerID=8YFLogxK

U2 - 10.2105/AJPH.2016.303382

DO - 10.2105/AJPH.2016.303382

M3 - Review article

C2 - 27631754

AN - SCOPUS:84990857135

VL - 106

SP - 2019

EP - 2025

JO - American Journal of Public Health

JF - American Journal of Public Health

SN - 0090-0036

IS - 11

ER -